Sort
48,018 grants matching “immunotherapy”
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$672,254Deborah W Knapp · Purdue University · U01 · FY2025 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors
$672,231Barry A Berkowitz · Bessor Pharma, Llc · R44 · FY2022 · CA
PD-1/PD-L1 modulation in cancer therapy
$672,206Drew M. Pardoll · Johns Hopkins University · R01 · FY2020 · CA
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation
$672,205Diane McMahon Pratt · Yale University · R01 · FY2011 · AI
IMMUNOMODULATION FOR ISLET TRANSPLANTATION IN DIABETES
$671,940University Of Miami School Of Medicine · R01 · FY2000 · DK
CAR-T cell treatment of CNS Autoimmunity
$671,939Gregory Wu · Washington University · R01 · FY2022 · AI
Defining correlates of protection from dengue illness in a long-term cohort study of multigenerational house-holds in Thailand
$671,876Kathryn B Anderson · Upstate Medical University · R01 · FY2024 · AI
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
$671,795David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Adaptive epigenetic mechanisms of beta and immune cells in autoimmune diabetes
$671,775Kevan C Herold · Yale University · R01 · FY2023 · DK
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy
$671,774Jennifer M Munson · Virginia Polytechnic Inst And St Univ · R01 · FY2022 · NS
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
$671,746Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R42 · FY2022 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
$671,730David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer Therapy
$671,728Richard Leo Wahl · Johns Hopkins University · U01 · FY2011 · CA
Outcomes for CLL patients treated with novel therapy
$671,624Neil E Kay · Mayo Clinic Rochester · R01 · FY2025 · CA
Role of AMPK in melanoma brain metastasis
$671,615Bin Zheng · Cedars-Sinai Medical Center · R01 · FY2025 · CA
A network approach to interrogate cellular plasticity and drug resistance in cancer
$671,594Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2024 · CA
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas
$671,445Crystal Mackall · Stanford University · R01 · FY2021 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$671,440Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2024 · CA
Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer
$671,146Ji Qiu · Arizona State University-Tempe Campus · R01 · FY2024 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$671,059Elad Ziv · University Of California, San Francisco · R01 · FY2021 · CA
Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
$671,046Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Multidisciplinary Collaborative Clinical Research, Core Facilities and Other Clinical Services in NIDDK Program Area Diseases
$671,045James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZID · FY2014 · DK
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$670,933Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2018 · CA
Phase I Clinical Trials of Anticancer Agents
$670,900Mayo Clinic · U01 · FY2005 · CA
Regulatory and effector T cells in oral immunotherapy for food allergy
$670,888Wayne G Shreffler · Massachusetts General Hospital · U19 · FY2015 · AI